From: Novo Nordisk (mail@communications.novonordisk.com)
Due to higher than anticipated demand, Novo Nordisk will be unable to provide the Sogroya 15 mg pen from Mid-February through May 2024. However, there is an ample supply of the 5mg and 10mg pens to address total overall Sogroya® demand and patient need moving forward. These other pen sizes are available as a solution for those patients who would otherwise use the 15mg pen. For patients that are currently using the 15mg pen, we recommend they speak with you about their treatment plan to determine the best course of action.
We have new resources and tools available to help you estimate which strength and # of pens to prescribe, based on a patient’s required weekly dose, including the Pen Selector Tool, already live on www.sogroyapro.com.
As long-standing partners within this community, we are working hard to resolve this issue and are committed to acting in the best interests of the patients and healthcare professionals we serve. To help patients, we are working with payers and specialty pharmacies to simplify the process for patients who will be transitioning from the 15mg pen to an alternate pen strength of Sogroya® during this short-term interruption.
In addition, for patients enrolled in the NovoCare® Patient Assistance Program (PAP), “verbal,” electronic (e-script), and fax prescriptions will be accepted for patients transitioning from the 15mg pen to an alternate pen strength of Sogroya®. For NovoCare® JumpStart™ patients, all pen strengths of Sogroya® will be available to new and existing patients until the 15mg pen becomes unavailable. Patients enrolled in the NovoCare® Patient Assistance Program (PAP) will move to the 5mg and/or 10mg pen during the short-term interruption of the 15mg pen.
We thank everyone for their patience and will continue to share updates as they become available to keep you, HCPs, patients, caregivers, and other stakeholders informed.
Sincerely,
Novo Nordisk
Sogroya® is a registered trademark of Novo Nordisk Health Care AG.
Novo Nordisk is a registered trademark of Novo Nordisk A/S.
All other trademarks, registered or unregistered, are the property of their respective owners.
©2024 Novo Nordisk All rights reserved. US24SOM00022 February 2024